Precigen, Inc. Q3 2025 Earnings Recap

Precigen's third quarter of 2025 demonstrated a strong commercial launch of its breakthrough treatment Papcemias, which received FDA approval in August, paving the way for it to become the standard of care for recurrent respiratory papillomatosis (RRP).

Key Takeaways

• Papcemias achieved FDA approval with a broad label, marking it as the first and only treatment for adults with RRP.
• The pivotal clinical trial results showed 51% of patients achieved a complete response with no surgery required for 12 months, and 86% experienced reduced surgical burden.
• Precigen's sales team has engaged 90% of target institutions, resulting in multiple national formulary approvals and over 100 patients registered in the Precigen patient services hub.
• Strong payer coverage is already in place, with over 80 million lives covered, facilitating rapid market access.